Rx Industry Post-M&A Integration, Part I
Executive Summary
The long-term market cap of big pharma relies heavily on R&D pipeline valuation. But, in the wake of recent merger activity, most pharma companies have focused on producing short-term cost reductions in order to impress the financial markets. There is a way to reconcile these two, preserving the best of long-term R&D assets while cutting costs in other areas.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.